NexImmune Management to Attend Upcoming Conferences
May 30, 2018 09:00 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., May 30, 2018 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that the company will be participating in the...
NexImmune Announces Management and Board Appointments
March 27, 2018 07:30 ET
|
Neximmune, Inc.
Scott Carmer appointed Chief Executive OfficerKristi Jones promoted to Chief Operating OfficerAlan Roemer appointed Chairman of the Board of Directors GAITHERSBURG, Md., March 27, 2018 (GLOBE...
NexImmune Raises $23 Million to Advance Endogenous Cellular ImmunoTherapy into Clinical Development
January 02, 2018 07:00 ET
|
Neximmune, Inc.
Series A financing co-led by ArrowMark Partners and Barer & Son CapitalFinancing supports initiation of Phase I/II trial of AIMTM ACT in relapsed/refractory Hematologic Malignancies in 2018 ...
NexImmune and The Leukemia & Lymphoma Society enter partnership for the development of AIM ACT™ in AML patients
October 17, 2017 07:15 ET
|
Neximmune, Inc.
GAITHERSBURG, Md., Oct. 17, 2017 (GLOBE NEWSWIRE) -- NexImmune and The Leukemia & Lymphoma Society (LLS) have entered a partnership to advance the Company’s novel cellular immunotherapy into...
NexImmune Acquired by a Consortium of Private Investors Led by Former Celgene and Medtronic CEOs
February 14, 2017 07:30 ET
|
Neximmune, Inc.
GAITHERSBURG, Md., Feb. 14, 2017 (GLOBE NEWSWIRE) -- NexImmune, a biopharmaceutical company developing novel immuno-therapeutics based on the Artificial Immune (AIM™) nanotechnology platform, today...